Skip to content
Cyramza(ramucirumab)
Cyramza (ramucirumab) is an antibody pharmaceutical. Ramucirumab was first approved as Cyramza on 2014-04-21. It is used to treat colorectal neoplasms, non-small-cell lung carcinoma, and stomach neoplasms in the USA. It has been approved in Europe to treat stomach neoplasms. The pharmaceutical is active against vascular endothelial growth factor receptor 2.
Download report
Favorite
Top 200 Pharmaceuticals by Retail Sales
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
Trade Name
FDA
EMA
Cyramza
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Ramucirumab
Tradename
Proper name
Company
Number
Date
Products
CyramzaramucirumabEli LillyN-125477 RX2014-04-21
2 products
Labels
FDA
EMA
Brand Name
Status
Last Update
cyramzaBiologic Licensing Application2020-06-12
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
colorectal neoplasms—D015179—
non-small-cell lung carcinoma—D002289—
stomach neoplasmsEFO_0003897D013274C16
Agency Specific
FDA
EMA
Expiration
Code
ramucirumab, Cyramza, Eli Lilly and Company
2026-05-10Orphan excl.
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01F: Monoclonal antibodies and antibody drug conjugates
— L01FG: Vegf/vegfr (vascular endothelial growth factor) inhibitors
— L01FG02: Ramucirumab
HCPCS
Code
Description
J9308
Injection, ramucirumab, 5 mg
Clinical
Clinical Trials
138 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Non-small-cell lung carcinomaD0022897224——29
Stomach neoplasmsD013274EFO_0003897C166156—326
AdenocarcinomaD0002305176—225
Lung neoplasmsD008175C34.90—72——8
Colorectal neoplasmsD015179422——8
Liver neoplasmsD008113EFO_1001513C22.0332——7
Breast neoplasmsD001943EFO_0003869C50221——5
Urologic neoplasmsD014571C64-C68—11——2
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369C80137———19
Renal cell carcinomaD00229232———4
Esophageal neoplasmsD004938C1533———4
Pancreatic neoplasmsD010190EFO_0003860C2522———3
Ovarian neoplasmsD010051EFO_0003893C5611———2
Fallopian tube neoplasmsD00518511———2
MelanomaD00854511———2
CholangiocarcinomaD018281C22.111———2
Thymus neoplasmsD013953C37—2———2
Transitional cell carcinomaD00229511———2
Show 19 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Urinary bladder neoplasmsD001749C671————1
Ovarian epithelial carcinomaD0000772161————1
Non-hodgkin lymphomaD008228C85.91————1
Healthy volunteers/patients—1————1
Mantle-cell lymphomaD020522C83.11————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRAMUCIRUMAB
INNramucirumab
Description
Ramucirumab (human mab)
Classification
Antibody
Drug classmonoclonal antibodies
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID947687-13-0
RxCUI1535922
ChEMBL IDCHEMBL1743062
ChEBI ID—
PubChem CID—
DrugBankDB05578
UNII IDD99YVK4L0X (ChemIDplus, GSRS)
Target
Agency Approved
KDR
KDR
Organism
Homo sapiens
Gene name
KDR
Gene synonyms
FLK1, VEGFR2
NCBI Gene ID
3791
Protein name
vascular endothelial growth factor receptor 2
Protein synonyms
CD309, Fetal liver kinase 1, fetal liver kinase-1, FLK-1, KDR, Kinase insert domain receptor, kinase insert domain receptor (a type III receptor tyrosine kinase), Protein-tyrosine kinase receptor flk-1, soluble VEGFR2, tyrosine kinase growth factor receptor
Uniprot ID
Q14178
Mouse ortholog
Kdr (16542)
vascular endothelial growth factor receptor 2 (Q8VCD0)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Cyramza - Eli Lilly
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 6,352 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
12,617 adverse events reported
View more details